当前位置: X-MOL 学术CA: Cancer J. Clin. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Cancer statistics, 2022
CA: A Cancer Journal for Clinicians ( IF 503.1 ) Pub Date : 2022-01-12 , DOI: 10.3322/caac.21708
Rebecca L Siegel 1 , Kimberly D Miller 1 , Hannah E Fuchs 1 , Ahmedin Jemal 1
Affiliation  

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes. Incidence data (through 2018) were collected by the Surveillance, Epidemiology, and End Results program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data (through 2019) were collected by the National Center for Health Statistics. In 2022, 1,918,030 new cancer cases and 609,360 cancer deaths are projected to occur in the United States, including approximately 350 deaths per day from lung cancer, the leading cause of cancer death. Incidence during 2014 through 2018 continued a slow increase for female breast cancer (by 0.5% annually) and remained stable for prostate cancer, despite a 4% to 6% annual increase for advanced disease since 2011. Consequently, the proportion of prostate cancer diagnosed at a distant stage increased from 3.9% to 8.2% over the past decade. In contrast, lung cancer incidence continued to decline steeply for advanced disease while rates for localized-stage increased suddenly by 4.5% annually, contributing to gains both in the proportion of localized-stage diagnoses (from 17% in 2004 to 28% in 2018) and 3-year relative survival (from 21% to 31%). Mortality patterns reflect incidence trends, with declines accelerating for lung cancer, slowing for breast cancer, and stabilizing for prostate cancer. In summary, progress has stagnated for breast and prostate cancers but strengthened for lung cancer, coinciding with changes in medical practice related to cancer screening and/or treatment. More targeted cancer control interventions and investment in improved early detection and treatment would facilitate reductions in cancer mortality.

中文翻译:

2022 年癌症统计数据

每年,美国癌症协会都会估计美国新发癌症病例和死亡人数,并汇编有关基于人群的癌症发生率和结果的最新数据。监测、流行病学和最终结果计划收集了发病率数据(截至 2018 年);国家癌症登记计划;和北美中央癌症登记协会。死亡率数据(截至 2019 年)由国家卫生统计中心收集。到 2022 年,预计美国将出现 1,918,030 例新癌症病例和 609,360 例癌症死亡,其中每天约有 350 人死于肺癌,肺癌是癌症死亡的主要原因。2014 年至 2018 年期间,女性乳腺癌的发病率继续缓慢增长(每年增长 0.5%),而前列腺癌的发病率保持稳定,尽管自 2011 年以来晚期疾病每年增加 4% 至 6%。因此,在过去十年中,在远期诊断出的前列腺癌的比例从 3.9% 增加到 8.2%。相比之下,晚期疾病的肺癌发病率继续急剧下降,而局部阶段的发病率每年突然增加 4.5%,这有助于提高局部阶段诊断的比例(从 2004 年的 17% 到 2018 年的 28%)和 3 年相对生存率(从 21% 到 31%)。死亡率模式反映了发病率趋势,肺癌的下降速度加快,乳腺癌的下降速度放缓,前列腺癌的下降速度趋于稳定。总之,乳腺癌和前列腺癌的进展停滞不前,但肺癌的进展却有所加强,这与与癌症筛查和/或治疗相关的医疗实践的变化相吻合。
更新日期:2022-02-10
down
wechat
bug